Invest and Sell Parabilis Medicines Stock

Parabilis Medicines stock price

Forge Price ¹

Price not yet available

Last Closed Trade ²

Close Date

xx/xx/xx

Last Closed Trade Price

$xx.xx

Last Funding Round (LFR)

Date

xx/xx/xx

Price per Share

$xx.xx

Access Stock Price

Parabilis Medicines funding rounds and valuation

Funding history chart

Funding round details

	Funding Date	Share Class	Amount Raised	Price per Share	Post-Money Valuation	Key Investors
	03/01/2024	Series E	$145MM	$xx.xx	$491.8MM	Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, Marshall Wace, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Symbiosis
Price per Share $xx.xx Shares Outstanding 23,281,563 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 8.0% Cumulative Cumulative Participating Participating Participation Cap 1000 Key Investors Alex Gorsky, Catalio Capital Management, Foresite Capital, General Catalyst, Marshall Wace, Nextech Invest, Ra Capital Management, Rock Springs Capital, Samsara Biocapital, Sixty Degree Capital, Symbiosis
	11/21/2022	Series D	$178MM	$xx.xx	$406.53MM	Arch Venture Partners, Casdin Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Fidelity, Gv, Hbm Healthcare Investments, Invus, Milky Way Investments, Pagsgroup, T. Rowe Price, Venbio Partners
Price per Share $xx.xx Shares Outstanding 16,537,979 Liquidation Pref Order 2 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.2x Dividend Rate 8.0% Cumulative Cumulative Participating Participating Participation Cap 1000 Key Investors Arch Venture Partners, Casdin Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Fidelity, Gv, Hbm Healthcare Investments, Invus, Milky Way Investments, Pagsgroup, T. Rowe Price, Venbio Partners
	03/01/2021	Series C	$107MM	$xx.xx	$262.08MM	6 Dimensions Capital, Blue Pool Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Gv, Invus, Venbio Partners
Price per Share $xx.xx Shares Outstanding 7,384,710 Liquidation Pref Order 3 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.4x Dividend Rate 8.0% Cumulative Cumulative Participating Participating Participation Cap 1000 Key Investors 6 Dimensions Capital, Blue Pool Capital, Cormorant Asset Management, Deerfield Management, Farallon Capital Management, Gv, Invus, Venbio Partners
	05/16/2018	Series B	$65.51MM	$xx.xx	$131.82MM	6 Dimensions Capital, Blue Pool Capital, Boyu Capital, Deerfield Management, Gv, Horizons Ventures, Lerrink Partners, Nan Fung Group, Wuxi Apptec Corporate Ventures
Price per Share $xx.xx Shares Outstanding 4,658,112 Liquidation Pref Order 4 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.3x Dividend Rate 8.0% Cumulative Cumulative Participating Participating Participation Cap 1000 Key Investors 6 Dimensions Capital, Blue Pool Capital, Boyu Capital, Deerfield Management, Gv, Horizons Ventures, Lerrink Partners, Nan Fung Group, Wuxi Apptec Corporate Ventures
	05/25/2016	Series A	$11.11MM	$xx.xx	$37.05MM	Deerfield Management
Price per Share $xx.xx Shares Outstanding 1,434,062 Liquidation Pref Order 5 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.1x Dividend Rate 8.0% Cumulative Cumulative Participating Participating Participation Cap 1000 Key Investors Deerfield Management

Access Stock Price

Parabilis Medicines stock FAQs

To buy and sell Parabilis Medicines stock

Can you buy Parabilis Medicines stock?

As Parabilis Medicines is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Parabilis Medicines, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

How to buy Parabilis Medicines stock?

To invest in a private company like Parabilis Medicines through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Parabilis Medicines stock?

Yes, you may sell the Parabilis Medicines stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Parabilis Medicines stock?

If you hold private company shares of Parabilis Medicines – whether as an employee or an early investor – Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Parabilis Medicines on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

To learn more about Parabilis Medicines stock

Is Parabilis Medicines a public company?

No, Parabilis Medicines is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Parabilis Medicines’ stock price?

Parabilis Medicines is a privately held company and therefore does not have a public stock price. However, you may access Parabilis Medicines private market stock price with Forge Data.

What is Parabilis Medicines’ stock ticker symbol?

Parabilis Medicines does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Leadership and board

Leadership

Mathai Mammen MD, Ph.D.

Chief Executive Officer & President

Rohin Mhatre Ph.D

Chief Technical Operations Officer

Gregory Miller MPH, MBA

Chief Business Officer

Keith Orford MD

Chief Medical Officer & Executive Vice President of Clinical and Translational Science

Kristen Stants MILR

Chief People Officer

Board

Jeffrey Leerink

Leerink Partners

Krishna Yeshwant MD

Alexis Borisy

Nextech Invest

Parabilis Medicines news and media highlights

Yahoo Finance 03/01/2024

FogPharma pulls in $145M to support cancer drug research

FogPharma elevated its financing with a series E funding round to continue its cancer pharmaceutical research expansion.

MedCity News 12/05/2022

FogPharma’s $178M Funding Leads Way as 7 Biotechs Raise Cash for Cancer Drugs.

FogPharma is preclinical, but not for long. The biotech’s Series D financing round lays the groundwork to bring its lead program into the clinic in mid-2023, as well as support development of the rest of its pipeline of peptide drugs.

Inside Precision Medicine 11/29/2022

FogPharma Nets $178M Series D to Tackle Tough Targets

FogPharma has netted a $178 Million Series D financing to develop Helicon polypeptide therapeutics against hard targets.

PR Newswire 09/23/2019

FogPharma Expands Leadership Team with Key Appointments

/PRNewswire/ -- FogPharma today announced the appointment of Fang Wang, Ph.D., as Vice President of Biology and Nancy Wilker, Ph.D., J.D., as Vice President...

Other companies like Parabilis Medicines in the BioTech & Pharma sector

Sector: Healthcare

Subsector: BioTech & Pharma

					Last Funding Round
Company		Forge Price	Forge Price Change ⁵	Last Closed Trade	Share Class	Post-Money Valuation	Price per Share	Amount Raised
	Affinia Therapeutics	--	--	$xx.xx	Series B	$365.7MM	$xx.xx	$110MM
	Altos Labs	--	--	$xx.xx	Series C	$6.33B	$xx.xx	$1.5B
	Colossal Biosciences	--	--	$xx.xx	Series C	$10.2B	$xx.xx	$200MM
	Detect	--	--	$xx.xx	Series C-1	$388.91MM	$xx.xx	$75MM
	Egenesis	--	--	$xx.xx	Series D	$332.59MM	$xx.xx	$90.96MM
	Isomorphic Labs	--	--	$xx.xx	--	--	--	--
	Kailera Therapeutics	--	--	$xx.xx	Series A-2 NV	$580.71MM	$xx.xx	$7.09MM
	Loyal	--	--	$xx.xx	Series B-5	$428.44MM	$xx.xx	$17.49MM
	Mammoth Biosciences	--	--	$xx.xx	Series D-2	$1.35B	$xx.xx	$107.74MM
	Precision Neuroscience	--	--	$xx.xx	Series C	$542.69MM	$xx.xx	$102MM

See All Companies

Updated on: Feb 13, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.

Parabilis Medicines stock